Skip to main content
. 2023 May 26;14:1158028. doi: 10.3389/fgene.2023.1158028

TABLE 7.

The relationship between the GRS and migraine comorbidities of anxiety and depression susceptibility.

GRS Migraine (N = 251) T or ORadj (95% CI) p Migraine (N = 251) T or ORadj (95% CI) p
No(N = 202) Anxiety (N = 49) No(N = 139) Depression (N = 112)
Mean ± SD 11.59 ± 2.45 11.00 ± 2.42 1.528 0.131 11.68 ± 2.47 11.22 ± 2.40 1.466 0.144
Groups, N (%)
 Q1 (4–9) 37 (18.32) 14 (28.57) ref 23 (16.55) 28 (25.00) ref
 Q2 (10–11) 62 (30.69) 16 (32.65) 0.48 (0.17–1.30) 0.149 40 (28.78) 38 (33.93) 0.97 (0.40–2.36) 0.939
 Q3 (12–13) 56 (27.72) 11 (22.45) 0.31 (0.11–0.89) 0.032 44 (31.66) 23 (20.54) 0.14 (0.19–1.25) 0.137
 Q4 (14–17) 47 (23.27) 8 (16.33) 0.28 (0.08–0.88) 0.034 32 (23.02) 23 (20.54) 0.07 (0.15–1.06) 0.068
p for trend 0.020 0.025

GRS: genetic risk scores. Total of 11 SNPs (rs11110359 and rs11568537 of SLC17A8; GRIK2 rs2227283; SHANK1 rs3745521; rs8065080 and rs222741 of TRPV1; TRPV3 rs7217270; TRPV4 rs3742037; rs17862920, rs10166942 and rs7577262 of TRPM8) were included in the calculation of GRS. ORadj (95% CI) adjusted factors: age, sex, BMI, marital status, nationality, educational level, smoking, alcohol, exercise, history of hypertension, history of diabetes, family history of diabetes, family history of migraine, PSQI grade.